Growth Metrics

Amneal Pharmaceuticals (AMRX) EPS (Weighted Average and Diluted) (2018 - 2025)

Amneal Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 8 years, most recently at $0.11 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at $0.11 for Q4 2025, up 210.0% from a year ago — trailing twelve months through Dec 2025 was $0.23 (up 160.53% YoY), and the annual figure for FY2025 was $0.22, up 157.89%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.11 at Amneal Pharmaceuticals, up from $0.01 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for AMRX hit a ceiling of $0.11 in Q4 2025 and a floor of -$0.8 in Q2 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $0.0 (2022), compared with a mean of -$0.07.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 400.0% in 2023, while the deepest fall reached 1800.0% in 2023.
  • Amneal Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.04 in 2021, then increased by 25.0% to -$0.03 in 2022, then crashed by 1800.0% to -$0.57 in 2023, then surged by 82.46% to -$0.1 in 2024, then surged by 210.0% to $0.11 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $0.11 (Q4 2025), $0.01 (Q3 2025), and $0.07 (Q2 2025) per Business Quant data.